Majority stake in AllPure Technologies extends SSB portfolio for single-use bioprocessing

Sartorius Stedim Biotech (SSB) has signed a contract to acquire the majority stake in US start-up AllPure Technologies LLC. The privately-owned company, based in New Oxford, Pennsylvania, US, has been operating on the market for four years, and in 2013 earned revenue of around $3 million (£1.8/€2.2 million) with 25 employees. AllPure specialises in single-use components for biopharmaceutical applications, such as aseptic sampling techniques.

Reinhard Vogt, member of SSB’s executive board, commented: “AllPure further completes our portfolio with innovative products that help our customers develop and manufacture their pharmaceutical drugs safer and more efficiently. I am really looking forward to working with the AllPure team and to all that we can accomplish together.”

Michael Zumbrum, president of AllPure, added: “We are excited to leverage Sartorius Stedim’s impressive R&D capabilities so that we can accelerate the launch of new products from AllPure. And SSB’s global reach and industry relationships grant access to considerably more customers, especially in Europe and Asia, which have tremendous potential for AllPure’s products.”

Sartorius Stedim Biotech, www.sartorius.com.